Browsing Tag
PCSK9 inhibitors
4 posts
Merck’s enlicitide slashes LDL-C by 55.8%: Could this daily pill replace PCSK9 injections?
Merck’s enlicitide cuts LDL-C by over 55% in Phase 3 trial. Could it become the first oral PCSK9 inhibitor to transform ASCVD treatment?
Top 5 PCSK9 inhibitor stocks to watch in 2025: From injectables to gene editing
Explore the top five PCSK9 inhibitor stocks—Amgen, Regeneron–Sanofi, Merck, Novartis, Verve—and what makes each a standout in cholesterol treatment in 2025.
Merck launches Phase 3 CORALreef program for PCSK9 inhibitor MK-0616
Pharmaceutical giant Merck has announced the initiation of its groundbreaking Phase 3 clinical program, CORALreef, focusing on MK-0616—a…
AstraZeneca acquires oral PCSK9 inhibitors from Dogma Therapeutics
Pharma giant AstraZeneca has signed a deal to acquire a preclinical oral PCSK9 inhibitor asset from Dogma Therapeutics,…